Hospital
Montefiore Mount Vernon Hospital
Montefiore Mount Vernon Hospital was paid $24.60M by Medicaid between Jan 2018 and Dec 2024, across 166 billing codes. Its largest line is H0040, Assertive community treatment program, per diem — 20% of everything it billed.
33Billing provider infoMONTEFIORE MOUNT VERNON HOSPITAL
MOUNT VERNON, NY 10550
MOUNT VERNON, NY 10550
33aNPI1992131320assigned 09/17/2013
33bProvider typePsychiatric Hospital Unit
28Total paid$24.60M
24GClaims329,080
24DCodes billed166
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in New York
Rank by total paid#7 of 33
Median peer was paid$171K
This provider vs. median144×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,699 | $295K | |
| 2019 | 30,344 | $1.50M | |
| 2020 | 57,453 | $3.62M | |
| 2021 | 75,100 | $4.38M | |
| 2022 | 66,304 | $6.05M | |
| 2023 | 61,464 | $5.54M | |
| 2024incomplete | 32,716 | $3.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0040 | Assertive community treatment program, per diem | 20% | 2,614 | 2,599 | $4.83M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 14% | 114,277 | 8,254 | $3.43M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 12,375 | 9,983 | $2.16M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | 8.4% | 10,025 | 3,914 | $2.06M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.9% | 8,276 | 6,969 | $1.70M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.4% | 8,984 | 6,966 | $1.32M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 6,214 | 4,784 | $841K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.3% | 4,848 | 4,236 | $822K |
| 80053 | Comprehensive metabolic panel | 2.9% | 12,370 | 11,770 | $720K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.9% | 2,346 | 2,272 | $711K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 5,059 | 1,543 | $628K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 2.5% | 5,285 | 4,064 | $610K |
154 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 1,850 | $531K |
| 99214 | Doctor's office visit, returning patient (more involved) | 2.1% | 2,775 | $521K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.9% | 2,963 | $460K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 6,529 | $408K |
| 97597 | 1.4% | 1,112 | $337K | |
| 99215 | Doctor's office visit, returning patient (complex) | 1.0% | 1,105 | $257K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 731 | $186K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 699 | $171K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,732 | $157K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,796 | $133K |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 775 | $117K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,958 | $115K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,853 | $105K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,102 | $97K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,274 | $95K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 905 | $75K |
| 82803 | <1% | 2,861 | $58K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 1,024 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,176 | $54K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,395 | $52K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 163 | $38K |
| 86850 | <1% | 946 | $36K | |
| 86480 | <1% | 539 | $33K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,843 | $33K |
| 80061 | Lipid panel | <1% | 3,033 | $32K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,417 | $31K |
| 86901 | <1% | 946 | $27K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,784 | $24K |
| 76830 | Ultrasound, transvaginal | <1% | 465 | $24K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 95 | $24K |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 488 | $24K |
| 97161 | <1% | 191 | $23K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 162 | $20K |
| G0378 | Hospital observation service, per hour | <1% | 13 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,955 | $18K |
| 86900 | <1% | 946 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,249 | $17K |
| H0034 | Medication training and support, per 15 minutes | <1% | 746 | $17K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $15K |
| 0012A | <1% | 363 | $14K | |
| 83880 | <1% | 669 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,296 | $13K |
| 85610 | <1% | 3,484 | $13K | |
| 0011A | <1% | 374 | $12K | |
| 88142 | <1% | 267 | $12K | |
| 81025 | <1% | 240 | $11K | |
| 90715 | <1% | 452 | $10K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,959 | $10K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 70 | $10K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 51 | $8K |
| 87536 | <1% | 86 | $8K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 27 | $7K |
| 76641 | <1% | 189 | $7K | |
| 12001 | <1% | 12 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,475 | $7K |
| 86769 | <1% | 262 | $7K | |
| 96127 | <1% | 1,839 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 243 | $6K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $6K |
| J3490 | Unclassified drugs | <1% | 485 | $5K |
| 81001 | <1% | 5,467 | $5K | |
| 96368 | <1% | 194 | $5K | |
| 76376 | <1% | 1,154 | $5K | |
| 0064A | <1% | 112 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 53 | $5K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 30 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 54 | $4K |
| 97010 | <1% | 55 | $4K | |
| 99386 | <1% | 39 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,790 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 71 | $3K |
| 29581 | <1% | 19 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,738 | $3K |
| 73630 | <1% | 555 | $3K | |
| 97014 | <1% | 41 | $2K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 32 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,933 | $2K |
| 0031A | <1% | 63 | $2K | |
| 90654 | <1% | 88 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 53 | $2K |
| 99442 | <1% | 13 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 26 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,129 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 166 | $2K |
| 86592 | <1% | 605 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 379 | $1K |
| 84484 | <1% | 1,704 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 585 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,969 | $1K |
| 86361 | <1% | 41 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 640 | $969.35 |
| 87088 | <1% | 968 | $953.81 | |
| 85730 | <1% | 2,019 | $920.25 | |
| 96367 | <1% | 15 | $863.76 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $816.58 |
| 90686 | <1% | 37 | $792.05 | |
| 73030 | <1% | 120 | $763.06 | |
| 80076 | <1% | 75 | $712.24 | |
| 99443 | <1% | 12 | $607.26 | |
| 84439 | <1% | 178 | $550.27 | |
| 73130 | <1% | 250 | $547.01 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 707 | $536.31 |
| 73610 | <1% | 96 | $520.05 | |
| 83735 | <1% | 1,368 | $496.39 | |
| 83690 | <1% | 2,446 | $460.10 | |
| 80069 | <1% | 16 | $424.54 | |
| 81003 | <1% | 206 | $400.08 | |
| 72100 | <1% | 50 | $390.21 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 90 | $338.83 |
| 82043 | <1% | 109 | $298.68 | |
| 80320 | <1% | 1,274 | $284.35 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 636 | $265.85 |
| 80329 | <1% | 288 | $253.85 | |
| 84702 | <1% | 209 | $237.50 | |
| 82550 | <1% | 882 | $219.06 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 703 | $194.35 |
| 82607 | <1% | 38 | $154.18 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 129 | $145.64 |
| 88399 | <1% | 14 | $126.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 828 | $124.99 |
| 96376 | <1% | 41 | $106.39 | |
| 73562 | <1% | 39 | $102.53 | |
| 86803 | <1% | 15 | $102.41 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 431 | $87.58 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 130 | $87.34 |
| D0120 | Dental checkup, returning patient | <1% | 13 | $83.52 |
| 85652 | <1% | 112 | $77.95 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 649 | $71.36 |
| 81002 | <1% | 169 | $67.93 | |
| 87340 | <1% | 43 | $65.06 | |
| J2704 | Injection, propofol, 10 mg | <1% | 42 | $54.57 |
| 86706 | <1% | 33 | $40.20 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 92 | $36.21 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 58 | $36.00 |
| 86141 | <1% | 82 | $30.75 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 43 | $24.75 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 40 | $16.07 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 74 | $8.83 |
| 87040 | <1% | 156 | $8.15 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 143 | $4.06 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15 | $3.50 |
| 81015 | <1% | 100 | $2.02 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 19 | $1.92 |
| 91301 | <1% | 356 | $1.80 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 53 | $1.05 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 12 | $0.76 |
| 99080 | 0% | 2,271 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 15 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 14 | $0.00 |
| 87070 | 0% | 12 | $0.00 | |
| 82150 | 0% | 13 | $0.00 | |
| 85379 | 0% | 12 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 57 | $0.00 |
| 87081 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOHN, RANDI (AVP, REGULATORY PLANNING)
| Provider | Location | Paid |
|---|---|---|
| Montefiore New Rochelle Hospital | New Rochelle, NY | $24.11M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.